Clinical Trial Update: Influence of Cytochrome P2B6 on Efavirenz Dose in HIV-infected Thai Patients [Phase 1]

View source ↗

Summary

Phase 1 clinical trial examining how CYP2B6 genetic variation affects efavirenz dosing in HIV-infected Thai patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• EFAVIRENZ (efavirenz)

Snippet

Sponsor: Mahidol University | Conditions: Cytochrome P-450 CYP2B6, Efavirenz | Phase 1 | Status: UNKNOWN